Bill Humphries joined Valeant Pharmaceuticals on January 2, 2017, as Executive Vice President, Company Group Chairman for Dermatology and OraPharma. Previously, he was appointed CEO of Merz North America in March 2012, where he served until December 2016. Prior to joining Merz, Mr. Humphries served as the President of Stiefel, a leader in global dermatology and skin health, where he spearheaded two major acquisitions, and led the global integration of Stiefel into GlaxoSmithKline. Mr. Humphries held multiple senior executive roles within Allergan, Inc., concluding as Vice President of the U.S. Skincare business. Mr. Humphries has more than 29 years of experience in the specialty pharmaceutical industry, with more than 26 of those years focused on the commercialization of dermatology specialty pharmaceutical products. He currently is the Chair of the North Carolina State University Global Luxury Management Board and serves on the Board of Clearside Biomedical, the Women’s Dermatologic Society Industry Advisory Board, the steering committee for Carolina Entrepreneurial Development, and the Aclaris Therapeutics Board.
My 1:1 Connection is: My father, who is a retired pharmaceutical executive and Ortho Dermatologics alumni. Ever since I entered the world of pharmaceuticals, and specifically dermatology, he’s been a tremendous mentor and patient teacher.
Mr. McMyne is responsible for the dermatology sales force. He has spent the majority of his career in the dermatology arena. Most recently he served as vice president of operations for Merz North America, Inc., where he launched a channel marketing team and led the integration of two key acquisitions into the company's dermatology portfolio. Prior to that, Mr. McMyne served in various commercial roles at Medicis Pharmaceuticals, including associate director of sales for dermatology. He also worked at CV Therapeutics and WES.
My 1:1 Connection is: Dr. Bob Kaplan, who I met decades ago when I first got into this industry and whom I now consider one of my closest friends.
Ms. Williams oversees the development and implementation of the marketing strategy for the dermatology organization. She has wide-ranging experience in the commercial health care segment including medical devices, pharmaceuticals, R&D, and manufacturing. She was previously senior marketing director for Merz North America, where she led strategic direction and tactical execution for a neuroscience portfolio that included biologic, pharmaceutical, and medical device products. Ms. Williams initially worked at Valeant from 2004 to 2006, and has since returned. She has additionally held positions at Eli Lilly and Alcami (formerly aai).
My 1:1 Connection is: I’m new to the business side of dermatology but not new to the patient side of dermatology. As a psoriasis patient, I understand the importance of a strong, trustful relationship with your dermatologist and the emotional value of a treatment that works for you. I feel lucky I can truly understand what my impact will be beyond the walls of my office.
Ed has a robust background in pharmaceuticals, including more than fifteen years in dermatology focused on medical and aesthetic marketing. Ed came to Valeant from the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc., where he was the Global Group Product Director overseeing marketing for a dermatology portfolio that increased net sales every year. Ed was also responsible for commercial business development, the company pipeline, alternate-selling channels and co-promotion agreements, including promotion of Stelara in psoriasis and Ertaczo in podiatry. Ed has been recognized at Valeant with the 2015 Chairman’s Award for Excellence and a 2016 Executive Vice President Leadership Award.
My 1:1 Connection is: Dermatology has been my professional focus for a long time but the personal relationships I have in the dermatology community are the most gratifying part of my experience.
Mr. Kreider began his pharmaceutical career with Pfizer, and recently led all aspects of marketing for Merz North America’s Ulthera business, a leading aesthetic device company. He joined Merz in 2013 as Director of Business Development, culminating with the successful commercial integration of Ulthera into Merz. Prior to Merz, he held sales and marketing leadership roles of increasing responsibility at Medicis, and later Valeant after its 2012 acquisition of the company. His Medicis career began in sales, launching Solodyn in 2006. He was promoted to Regional Manager in 2008 and quickly revived the Florida region. Mr. Kreider then moved into marketing in 2010, taking over Vanos and was then entrusted with the relaunch of Zyclara.
My 1:1 Connection is: Michael McMyne, Jack Nicoll, and Dr. Jeff Suchniak were some of the first people I met when I started working in the dermatology field in 2006—and I have continued to work with all of them, call on them for advice, and count them among my friends for the past 10+ years. My favorite part of being in this industry is the connections you make with the people.
Mr. Hahn joined Valeant in 2011 as Director, Professional Relations for Valeant Dermatology. Previously, Mr. Hahn worked at the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc., for more than 20 years, holding positions of responsibility, including Director of Professional Relations, where he oversaw key opinion leader programs for both general and aesthetic dermatology. During Mr. Hahn's tenure at Ortho Dermatologics, he won the Sales Leader Club Award three times. More recently, he won the Executive Vice President Leadership Award. Mr. Hahn has more than 27 years of experience in the specialty pharmaceutical industry.
My 1:1 Connection is: I spent over 20 years working at Ortho Dermatologics; so being part of this new exciting Ortho Dermatologics story is like coming home for me.